Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Switch maintenance endocrine therapy plus bevacizumab after bevacizumab plus paclitaxel in advanced or metastatic oestrogen receptor-positive, HER2-negative breast cancer (BOOSTER): a randomised, open-label, phase 2 trial.
Saji S, Taira N, Kitada M, Takano T, Takada M, Ohtake T, Toyama T, Kikawa Y, Hasegawa Y, Fujisawa T, Kashiwaba M, Ishida T, Nakamura R, Yamamoto Y, Toh U, Iwata H, Masuda N, Morita S, Ohno S, Toi M. Saji S, et al. Among authors: toh u. Lancet Oncol. 2022 May;23(5):636-649. doi: 10.1016/S1470-2045(22)00196-6. Epub 2022 Apr 8. Lancet Oncol. 2022. PMID: 35405087 Clinical Trial.
Observational study of axilla treatment for breast cancer patients with 1-3 positive micrometastases or macrometastases in sentinel lymph nodes.
Oba MS, Imoto S, Toh U, Wada N, Kawada M, Kitada M, Masuda N, Taguchi T, Minami S, Jinno H, Sakamoto J, Morita S; Japanese Society for Sentinel Node Navigation Surgery. Oba MS, et al. Among authors: toh u. Jpn J Clin Oncol. 2014 Sep;44(9):876-9. doi: 10.1093/jjco/hyu090. Epub 2014 Jul 16. Jpn J Clin Oncol. 2014. PMID: 25030214 Clinical Trial.
Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.
Nishimura R, Toh U, Tanaka M, Saimura M, Okumura Y, Saito T, Tanaka T, Teraoka M, Shimada K, Katayama K, Koga T, Kurashita K, Hasegawa S, Todoroki H, Kai Y, Ohi Y, Toyoshima S, Arima N, Mitsuyama S, Tamura K. Nishimura R, et al. Among authors: toh u. Oncology. 2017;93(1):51-61. doi: 10.1159/000468521. Epub 2017 May 6. Oncology. 2017. PMID: 28478451
Prospective observational study of bevacizumab combined with paclitaxel as first- or second-line chemotherapy for locally advanced or metastatic breast cancer: the JBCRG-C05 (B-SHARE) study.
Yamamoto Y, Yamashiro H, Toh U, Kondo N, Nakamura R, Kashiwaba M, Takahashi M, Tsugawa K, Ishikawa T, Nakayama T, Ohtani S, Takano T, Fujisawa T, Toyama T, Kawaguchi H, Mashino K, Tanino Y, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: toh u. Breast Cancer. 2021 Jan;28(1):145-160. doi: 10.1007/s12282-020-01138-4. Epub 2020 Jul 26. Breast Cancer. 2021. PMID: 32715420 Free PMC article.
80 results